Immune-mediated renal disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Immune-mediated renal disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-adx-038-in-patients-with-complement-mediated-kidney-disease/ Wed, 29 Apr 2026 15:09:15 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-adx-038-in-patients-with-complement-mediated-kidney-disease/ This study focuses on individuals living with Complement-Mediated Kidney Disease, a rare condition where the immune system’s proteins, known as the complement system, mistakenly attack the kidneys. The investigation aims to evaluate the safety and tolerability of the drug ADX-038. This medication is administered via a subcutaneous injection, which is a method of delivering medicine through a small needle just under the skin.

During the course of the study, participants will receive the study drug to monitor how the body reacts to it. Researchers will observe the effects of ADX-038 over time, specifically looking for any side effects or changes in the amount of protein released in the urine, which is often measured through a UPCR (urine protein-to-creatinine ratio) test. This test helps in understanding how well the kidneys are functioning.

]]> Study on the Safety and Effects of ARO-C3 for Adults with Complement-Mediated Kidney Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aro-c3-for-adults-with-complement-mediated-kidney-disease/ Wed, 29 Apr 2026 14:25:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aro-c3-for-adults-with-complement-mediated-kidney-disease/ This clinical trial is focused on studying a condition known as complement-mediated renal disease, which affects the kidneys. The trial will explore the effects of a new treatment called ARO-C3, which is a solution for injection. ARO-C3 contains an active substance known as ADS-011, a type of synthetic, double-stranded, small interfering RNA (siRNA) that is designed to target specific processes in the body. The study aims to understand how safe and tolerable ARO-C3 is for patients, as well as how it behaves in the body over time.

The trial will involve adult participants, including both healthy volunteers and those with complement-mediated renal disease. Participants will receive multiple doses of ARO-C3 through subcutaneous injection, which means the injection is given under the skin. The study will monitor participants for any side effects and measure how the drug is processed by the body. Additionally, researchers will observe changes in certain proteins in the blood that are related to the disease.

The purpose of this study is to gather important information about ARO-C3, which could potentially lead to new treatment options for people with complement-mediated renal disease. The trial will take place over a period of time, with participants attending scheduled visits to receive the treatment and undergo various assessments. This research is an important step in understanding how ARO-C3 can help manage this kidney condition.

]]>